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A B S T R A C T
Background: The standard agglutination (SAT) and 2-mercaptoethanol (2-ME) tests are usually used in
the follow-up of treated cases of human brucellosis. The purpose of this study was to monitor the levels
of these tests, two years after clinical cure in cases of brucellosis.
Methods: From April 2003 to September 2008, 175 clinically cured cases of brucellosis (103 males, 72
females) were evaluated. Diagnosis of brucellosis was established with a SAT of 1:320 and a 2-ME of
1:80, with clinical symptoms and signs compatible with brucellosis. SAT and 2-MEwere retested at the
end of therapy and at 3-monthly intervals for two years. Serologic cure was considered in the event of a
SAT titer decrease to 1:160 or a 2-ME decrease to < 1:80.
Results: The mean age of study patients was 31  13.5 years. At 6, 12, 18, and 24 months after treatment,
SAT titers 1:320 were seen in 41 (23.4%), 22 (12.6%), 7 (4%), and 6 (3.4%) cases, respectively, whereas 2-ME
titers1:80 were seen in 51 (29.1%), 24 (13.7%), 12 (6.9%), and 8 (4.6%) cases, respectively. The probability of
serologic cure for patients with SAT titers1:640 was higher than for those>1:640 (95% conﬁdence interval
(CI) 2.5–3.47, p = 0.023). The probability of serologic cure for patients with 2-ME titers 1:320 was higher
than for those >1:320 (95% CI 2.48–3.5, p = 0.04).
Conclusions: SAT and 2-ME may be found in signiﬁcant titers in less than 5% of clinically treated cases
after two years. Serologic cure for both tests with lower titers were higher than with higher titers.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Brucellosis is an important public health problem in many
countries throughout the world, including Iran.1,2 The deﬁnitive
diagnosis of patients with brucellosis is isolation of the organism
from the blood or other body ﬂuids, however isolation of the
organism is achieved in 10–70%.3,4 A standard agglutination test
(SAT) titer 1:320 and 2-mercaptoethanol (2-ME) titer 1:80 in
patients with compatible clinical ﬁndings are the most important
methods for diagnosing brucellosis in developing countries.
In endemic areas, >90% of patients with acute bacteremia have
SAT titers of at least 1:320.5,6 The SATmeasures the total amount of
agglutinating antibodies of IgM and IgG, and the 2-ME test
measures IgG antibodies and strongly indicates active infection. A
rapid fall in the level of IgG antibodies is prognostic of successful
therapy.7 Relapse may occur with any therapy regimen.8–13 Thus
patients should ideally be followed clinically and serologically for* Corresponding author. Tel.: +98 111 3232962; fax: +98 111 2227667.
E-mail address: hagar2q@yahoo.ca (M.R.H. Roushan).
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doi:10.1016/j.ijid.2009.05.008up to two years to detect any case of relapse. IgG antibody levels
detected by SAT and variants of this test can remain in the
diagnostic range for more than two years after successful
treatment.4 Thus it is warranted to caution against treating
positive titers in those asymptomatic patients previously treated
for brucellosis. A resurgence in antibody titersmost likely indicates
relapse or reinfection.14 A fall in the 2-ME titer reﬂects a
satisfactory response to treatment. It indicates a favorable
response to antibiotic therapy and that no further antibiotic
treatment is required.7 Since reports of the serologic follow-up of
successfully treated cases are limited in the medical literature, the
purpose of this study was to assess the follow-up titers of SAT and
2-ME in clinically treated cases of brucellosis.
2. Methods
From April 2003 to September 2008, 175 clinically cured cases
of brucellosis, followed for two years at the Department of
Infectious Diseases of Babol Medical University in Iran, were
studied. These cases were selected from patients whowere treated
either with streptomycin 1 g IM for two weeks and doxycyclineses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Probability for cure with SAT titers >1:640 and 1:640 in patients with
brucellosis whowere successfully cured. The log rank test shows that the difference
was signiﬁcant (p = 0.023).
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kg/day for seven days plus the same dose of doxycycline for 45
days (105 cases). Brucellosis in these patients was diagnosedwhen
they had a SAT titer 1:320 and 2-ME titer 1:80 with clinical
signs and symptoms compatible with brucellosis.
In treated cases, ‘clinical cure’ was deﬁned as resolution of all
clinical symptoms and signs of brucellosis after the end of
treatment. The aim of this study was to determine serologic cure
(SAT or 2-ME) in cured cases of brucellosis during a two-year
follow-up. Falls in titer of SAT or 2-ME over time are prognostic of a
good response to therapy.1,3,13 Therapeutic failure due to lack of
efﬁcacy was deﬁned by symptoms or signs of the disease that
persisted at the end of treatment as judged clinically. Relapse was
deﬁned to have occurred when clinical symptoms and signs of
brucellosis reappeared after completion of therapy and reduced
titers of SAT or 2-ME increased again.3 Cases of initial therapeutic
failure and relapse and those who were not followed for two years
were excluded from the study. SAT and 2-ME titers were recorded
at baseline, after treatment, and at three-monthly intervals for two
years. SAT and 2-ME test antigen was obtained from the Institute
Pasteur, Iran and tests were interpreted according to routine
methods and criteria. SAT and 2-ME were performed in glass
reaction tubes and the agglutination was observed under light in
each tube. Serologic cure in clinically cured subjects was
determined when the titers of SAT and 2-ME decreased to less
than 1:320 and 1:80, respectively. The study was approved by the
Infectious Diseases Research Center of the Babol Medical
University.
Datawere analyzed using SPSS version 15 (SPSS Inc., Chicago, IL,
USA). The reductions in SAT and 2-ME titers over time were
determined in all cases. The log rank test was used to compare SAT
cure in patients with titers1:640 and>1:640 as well as serologic
cure of 2-ME1:320 and>1:320. Times for reduction of SAT and 2-
MEwere depicted using Kaplan–Meier graphs. Ninety-ﬁve percent
conﬁdence intervals (CIs) were calculated when appropriate.
Differences with a p-value of < 0.05 were considered signiﬁcant.
3. Results
In the gentamicin and doxycycline treated patients, seven cases
had initial therapeutic failure or relapse and six patients did not
participate in our follow-up and were excluded from the study. In
the streptomycin and doxycycline treated patients, nine cases had
initial therapeutic failure or relapse and seven subjects did not
participate in our follow-up period and were excluded from the
study. Hence, a total of 16 (7.8%) cases were not clinically or
serologically responsive and 13 (6.4%) did not participate in our
follow-up study. Therefore, 175 clinically cured cases in both
treated groups (103 males and 72 females), with a mean age of 31
 13.5 years, who were followed for two years, were evaluated.
SAT titers of between 1:320 and 1:1280 were seen in 166
(94.9%) cases before the initiation of therapy. After treatment, SAT
titers <1:320 were seen in 42 (24%) of the cases. Despite clinical
cure, SAT and 2-ME titers were increased compared to baselineTable 1
SAT titers at baseline, at the end of therapy, and at follow-up over two years, for 175
SAT <1:40 1:80 1:160
At baseline - - -
At end of treatment 6 (3.4) 14 (8) 22 (12.6)
3 months later 47 (26.9) 33 (18.9) 33 (18.9)
6 months later 82 (46.9) 32 (18.3) 20 (11.4)
12 months later 119 (68) 23 (13.1) 11 (6.3)
18 months later 150 (85.7) 8 (4.6) 10 (5.7)
24 months later 154 (88) 10 (5.7) 5 (2.9)
Results are n (%).
SAT, standard agglutination test.levels in six (3.4%) and 10 (5.7%) cases, respectively, although in
these cases, the levels of SAT or 2-ME fell below the baseline levels
after three months. At six and 12 months after treatment, SAT
<1:320 was seen in 134 (76.6%) and 153 (87.4%) cases,
respectively. Eighteen and 24 months after treatment SAT titers
1:320 were seen in seven (4%) and six (3.4%) patients,
respectively (Table 1). The probability of serologic cure of SAT
for patients with titers 1:640 was higher than for those >1:640
(95% CI 2.5–3.47, p = 0.023) (Figure 1).
At baseline, 2-ME titers 1:160 were seen in 127 (72.6%) cases
(Table 2). After six and 12 months of treatment, 2-ME titers 1:80
were seen in 51 (29.1%) and 24 (13.7%) cases, respectively.
Eighteen and 24 months after treatment, 2-ME 1:80 was seen in
12 (6.9%) and eight (4.6%) cases, respectively (Table 2). The
probability of serologic cure for the 2-ME test in patients with
titers 1:320 was higher than for those >1:320 (95% CI 2.48–3.5,
p = 0.04) (Figure 2).
4. Discussion
In this study, we found that SAT serologic cure increased from
42 (24%) patients at the end of treatment to 153 (87.4%) one year
after treatment. This rate increased to 96.6% after two years. The
cure rate for the 2-ME test was 17.1% at the end of treatment and
was 86.3% after one year. Only eight (4.6%) cases had signiﬁcant
titers for 2-ME after two years. Serologic cure for both tests in
patients with lower titers were higher than with higher titers.treated cases of brucellosis
1:320 1:640 1:1280 1:2560 1:5120
69 (39.4) 50 (28.6) 47 (26.9) 8 (4.6) 1 (0.6)
59 (33.7) 38 (21.7) 30 (17.1) 5 (2.9) 1 (0.6)
24 (13.7) 30 (17.1) 5 (2.9) 2 (1.1) 1 (0.6)
23 (13.1) 12 (6.9) 6 (3.4) 0 (0) 0 (0)
15 (8.6) 6 (3.4) 1 (0.6) 0 (0) 0 (0)
3 (1.7) 4 (2.3) 0 (0) 0 (0) 0 (0)
4 (2.3) 2 (1.1) 0 (0) 0 (0) 0 (0)
Table 2
2-ME titers at baseline, at the end of therapy, and at follow-up over two years, for 175 treated cases of brucellosis
2-ME 0 1:20 1:40 1:80 1:160 1:320 1:640 1:1280
At the baseline - - - 48 (27.4) 57 (32.6) 42 (24) 20 (11.4) 8 (4.6)
End of therapy 9 (5.1) 5 (2.9) 16 (9.1) 46 (26.3) 56 (32) 27 (15.4) 11 (6.3) 5 (2.9)
3 months later 48 (27.4) 16 (9.1) 32 (18.3) 33 (18.9) 31 (17.7) 13 (7.4) 2 (1.1) 0 (0)
6 months later 85 (48.6) 12 (6.9) 27 (15.4) 31 (17.7) 12 (6.9) 6 (3.4) 2 (1.1) 0 (0)
12 months later 124 (70.9) 6 (3.4) 21 (12) 15 (8.6) 5 (2.9) 3 (1.7) 1 (0.6) 0 (0)
18 months later 152 (86.9) 3 (1.7) 8 (4.6) 8 (4.6) 1 (0.6) 2 (1.1) 1 (0.6) 0 (0)
24 months later 152 (86.9) 6 (3.4) 9 (5.1) 5 (2.9) 1 (0.6) 2 (1.1) 0 (0) 0 (0)
Results are n (%).
2-ME, 2-mercaptoethanol.
Figure 2. Probability for serologic cure with 2-ME titers >1:320 and 1:320 in
patients with brucellosis who were successfully cured. The log rank test shows that
the difference was signiﬁcant (p = 0.04).
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1:640 or 2-ME 1:320 at the time of diagnosis lost their speciﬁc
antibodies rapidly. Thus, patients with higher titers of SAT or 2-ME
at baseline may have signiﬁcant titers of both tests after early
post-treatment follow-up. On the other hand, we found that SAT
and 2-ME titers increased compared to baseline levels in six (3.4%)
and 10 (5.7%) cases, respectively, but the titers fell below baseline
levels after three months of post-treatment follow-up. These
ﬁndings emphasize that serologic titers should be interpretedwith
caution in clinically cured cases, especially in early post-treatment
follow-up.
Serologic tests are not only the most commonly used tests for
the diagnosis of brucellosis in endemic regions, but these tests are
also useful for follow-up of treated cases in order to determine
relapse. Most relapses occur within six months of cessation of
therapy.15 With recovery, titers of IgG and IgM antibodies slowly
decline; large numbers of cases do not have signiﬁcant titers for
both antibodies after one year, as we have shown in this study.16,17
Almuneef and Memish followed 116 clinically cured cases of acute
brucellosis in Saudi Arabia and found that 28.6% of their cases had
signiﬁcant titers of SAT after two years. They also found that older
age, male gender, and patients treated with fewer than three
antibiotics were more likely to have persistently high Brucella
antibodies. They showed that a doxycycline-containing regimen of
therapy was associated with serologic cure.18 Buchanan and Faber
showed that the titers remained positive in the SAT test muchlonger than in the 2-ME test and 48% of their 92 cases had SAT titers
of 1:160, 1.5 years after treatment was begun. However,
regarding the 2-ME test, the number of patients with titers of
1:160 at 6, 9, 12, and 18 months after illness were 22 (24%), 12
(13%), 8 (9%), and 4 (4%), respectively.7 The differences in the fall of
SAT titers in the two above studies compared to our study may be
related to the high titers of SAT in their cases at the time of
diagnosis and treatment. On the other hand, the therapy regimens
that were used in our study may have inﬂuenced the rapid fall in
titers of SAT in our cases. Regarding falling titers of 2-ME, our
results are in agreement with the ﬁndings of Buchanan and Faber
and Mantur et al.7,19 A fall in the 2-ME titer reﬂects a satisfactory
response to treatment. It indicates a favorable response to
antibiotic therapy and that no further antibiotic treatment is
required.20
Recently, investigators have shown Brucella DNA in the sera of a
signiﬁcant number of successfully treated cases who had remained
clinically healthy for prolonged follow-up periods, without ﬁnding
any organism. They concluded that clinical response may not be
equivalent to pathogen eradication in brucellosis patients.21,22 This
question is particularly important in the brucellosis endemic
regions. On the other hand, asymptomatic bacteriologic relapse is a
problem for clinicians working in underdeveloped nations. We
believe that until the answers to these questions are found, clinical
and serologic follow-up may be the best way to monitor these
cases. Thus, caution iswarranted against treating positive titers per
se to make them disappear in those asymptomatic patients
previously treated for brucellosis. The availability of these tests is
useful for the diagnosis of human brucellosis, especially in
developing countries where most of the modern facilities are
not available. The results of this study show that SAT and 2-ME
may occur in signiﬁcant titers in less than 5% of clinically cured
cases after two years. Serologic cure for both tests with lower titers
were higher than with higher titers.
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